Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 109Radiotherapy 106Fluorouracil 76Doxorubicin 74Carboplatin 71Etoposide 67Cisplatin 67Vincristine 66Paclitaxel 58Chemotherapy, Adjuvant 53Leucovorin 47Specimen Handling 43Cytarabine 42Magnetic Resonance Spectroscopy 38Methotrexate 37Dexamethasone 33Taxes 31Bevacizumab 31Peripheral Blood Stem Cell Transplantation 30Gemcitabine 30Filgrastim 30Docetaxel 30Tamoxifen 28Melphalan 28Immunoglobulin G 25Epirubicin 25Disulfides 25Oxaliplatin 24Daunorubicin 24Prednisone 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NIH × Pyridoxine × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡